1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

09 Mar 2024
Admin
News Article

Johnson & Johnson Acquires Ambrx

Overview

Johnson & Johnson (NYSE: JNJ) announced the successful completion of its acquisition of Ambrx Biopharma, Inc., a clinical-stage biopharmaceutical company known for its proprietary synthetic biology technology platform aimed at designing and developing next-generation antibody drug conjugates (ADCs). This acquisition, conducted through an all-cash merger transaction valued at approximately $2.0 billion, or $1.9 billion net of estimated cash acquired, was initially announced on January 8, 2024. The transaction will be treated as a business combination.

J & J on Acquisition

"We are delighted to welcome the talented scientific team and unique ADC platform of Ambrx into the Johnson & Johnson family,"" said Dr. Yusri Elsayed, MD, MHSc, PhD, Global Therapeutic Area Head of Oncology at Johnson & Johnson Innovative Medicine. ""We are particularly excited about the potential of ARX517, a PSMA-targeting ADC, as a potential first- and best-in-class treatment for metastatic castration-resistant prostate cancer. This acquisition positions us to advance the development of next-generation ADCs, with the goal of delivering innovative therapies for solid tumors that can significantly improve patients' lives."

Strengths of Both Parties

This strategic move provides Johnson & Johnson with an opportunity to lead in the design, development, and commercialization of targeted oncology treatments.
Ambrx's ADC technology offers a unique approach, leveraging highly specific monoclonal antibodies linked to potent chemotherapeutic payloads.
This enables targeted and efficient elimination of cancer cells while mitigating the common side effects associated with traditional chemotherapy.

ADCs Against Solid Tumors

"Bolstering our oncology innovation strategy, the acquisition of Ambrx and its promising pipeline of ADCs strengthens our position in the oncology space,"" commented Biljana Naumovic, Worldwide Vice President of Oncology at Johnson & Johnson Innovative Medicine. ""ADCs represent a significant advancement in the treatment of solid tumors, harnessing the power of antibody-antigen interactions to deliver cytotoxic payloads directly to cancer cells. This acquisition reflects our commitment to delivering precision biologics that can transform cancer treatment, including prostate cancer.""

Summary

In summary, Johnson & Johnson's acquisition of Ambrx marks a strategic step towards advancing precision oncology therapeutics, with the potential to revolutionize the treatment landscape for solid tumors, including prostate cancer.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!